TX-FLUENCE
29.2.2024 14:31:32 CET | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced its newest LED top light solutions for produce and ornamental cultivators: RAPTR 2 and VYPR 4.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229846318/en/
Fluence announced its newest LED top light solutions for produce and ornamental cultivators: RAPTR 2 and VYPR 4. (Photo: Business Wire)
Fluence’s latest LED innovations were developed in parallel with the company’s global research program, which includes partnerships with industry leaders worldwide and in-house analysis of spectral optimization across crops. The new RAPTR and VYPR offerings build upon Fluence’s existing portfolio of lighting solutions to offer robust fixtures with higher wattages, greater efficiencies and overall increased ROI for growers throughout the world.
RAPTR 2: Higher wattages and tunable spectra help growers maximize light output and efficiency at lower installation costs
The RAPTR 2 fixture’s wide power range (up to 1400 W), multi-channel tunable spectra and up to 5050 μmol/s of light output make it the optimal lighting solution for upgrading HPS fixtures in greenhouse environments. Featuring steerable spectra—including far red—integrated wireless dimming capability and efficacies up to 4.0 μmol/J, cultivators can achieve improved crop performance and lower operating expenses with the new RAPTR 2.
“The latest RAPTR and VYPR series luminaires showcase that Fluence’s primary mission remains unchanged: Help the world grow smarter through the most advanced LED fixtures,” said Steve Graves, senior vice president of strategy and business development at Fluence. “We're excited to launch our most powerful and efficient solutions yet and we look forward to advancing the industry together with partners across the globe.”
VYPR 4: More versatility and control that maximizes cultivation results
Featuring the VYPR line’s familiar low-profile design, VYPR 4 offers more spectral options, light uniformity at any mounting height, easy installation and higher light intensities with lower energy consumption.
“VYPR 4 is a versatile top light solution,” said Jordon Musser, chief product officer for Fluence. “The latest generation focuses on what every grower wants: a more efficient output that yields a clear ROI. Installation is swift, the fixtures are extremely durable, and growers can tap into Fluence’s diverse spectral options to curate a lighting program unique to their cultivation goals.”
VYPR 4 features output up to 3030 μmol/s and efficiency up to 3.9 μmol/J. The fixture also includes dual-channel far red spectra as well as Fluence’s wide variety of PhysioSpec™ spectra to empower growers with multiple lighting strategies. VYPR 4’s low profile creates the least possible shading in a greenhouse environment and now offers a wide-beam optic for optimized light distribution.
Fluence will showcase RAPTR 2 and VYPR 4 during its upcoming global trade shows, including HortiContact from March 5 to March 7, 2024 in the Netherlands.
To learn more about the RAPTR and VYPR series and how to schedule a trial at your facility, visit www.fluence-led.com.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis, produce and flower markets, committed to enabling more efficient crop production for the world’s top greenhouse and indoor growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Professional Business. For more information about Fluence, visit www.fluence-led.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229846318/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients8.4.2026 08:15:00 CEST | Press release
This record closing is the largest raise ever achieved by a fully independent European fund dedicated to Biopharma, validating Jeito’s patient-driven investment strategy, its multidisciplinary, collaborative expertise spanning from science to commercialization of medicines, and value creationIn five years, Jeito Capital has tripled its assets under management to €1.6 billion, firmly establishing itself among the top-tier global Biopharma investorsJeito II will build on Jeito I’s proven and differentiated strategy, investing in the most promising clinical Biopharma companies which address unmet patient needs and severe diseases, accelerate breakthrough therapeutic innovation, and deliver transformative benefits for patientsThis fundraise represents significant momentum for European Biopharma, strengthening its financial firepower and expertise to develop the next generation of global champions Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, toda
Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 07:00:00 CEST | Press release
Hyaluronic acid product for knee osteoarthritis available in the EU and Switzerland from May 2026 Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of
Murata Begins Mass Production of Seven Automotive MLCCs with World-leading Capacitance for Their Rated Voltage and Size, Supporting Stable Operation of In-vehicle Systems and Greater Design Flexibility8.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of seven AEC-Q200-qualified multilayer ceramic capacitors (MLCCs) that achieve the world’s largest capacitance for a given rated voltage and size*, supporting stable operation of in-vehicle systems and greater design flexibility. Five parts in the GCM series are rated at 2.5-4 Vdc, targeting IC peripheral circuits in advanced driver assistance systems (ADAS) and autonomous driving (AD) applications. The remaining two MLCCs are rated at 25 Vdc for in-vehicle power line applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407486750/en/ [Murata Manufacturing Co., Ltd.] Seven automotive MLCCs In recent years, as ADAS and AD technologies advance, the number and performance level of systems installed in vehicles have continued to increase. As a result, demand for higher capacitance low-voltage MLCCs used around ICs has grown to e
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)7.4.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees. The equity awards were granted on April 1, 2026 and consisted of options to purchase an aggregate of 117,445 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 55,875 shares. The options have an exercise price per share equal to $5.62, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted s
SLB OneSubsea and Subsea7 Sign Collaboration Agreement with PETRONAS Suriname7.4.2026 22:05:00 CEST | Press release
Partnership enables early engagement to co-develop cost-effective solutions and accelerate subsea development in Suriname Global energy technology company SLB (NYSE: SLB) today announced the signing of a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331210557/en/ SLB OneSubsea has signed a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea soluti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom